The signal pathway for the repressive effect of dipyridamole on myofibroblast transdifferentiation

Yan, Qiong; Ina, Keisuke; Chiba, Seiichi; Wei, Huixing; Tatsukawa, Shuji; Fujikura, Yoshihisa

doi:10.1111/jcmm.14006

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24 This inhibitory intervention ultimately leads to a decline in cyclic adenosine monophosphate cell concentration and a decreased response to dipyridamole infusion. 25 We proposed that the effect of beta-blockers by receptor inhibition reduces the sensitivity to dipyridamole and decreases vascular response; however, the determination of the exact mechanism needs more evaluation.…”

Section: Discussionmentioning

confidence: 99%

Effect of Beta-Blocker Consumption on the Severity and Extension of Perfusion Defects in Dipyridamole Myocardial Perfusion Single-Photon Emission Computed Tomography

Shahlaee,

Falsoleiman,

Daloee

et al. 2024

World J Nucl Med

View full text Add to dashboard Cite

Background Regarding the less-known effects of beta-blocker consumption on the diagnostic value of the myocardial perfusion scan with dipyridamole stress in coronary artery disease (CAD), we aimed to compare the findings of the scans done on the beta-blocker consumption course and after discontinuation of this medications. Materials and Methods Thirty patients with probably CAD and abnormal myocardial perfusion scans (presence of reversible defect), who had been treated with beta-blockers for at least 3 months, were studied. Dipyridamole stress phase of myocardial perfusion single-photon emission computed tomography (SPECT) was performed two times with an interval of about 1 week, once after discontinuation of all antianginal and anti-ischemic medications, statins, and beta-blockers for 72 hours prior to the study, and again after discontinuation of all these medications except for beta-blockers. Imaging was done with the same protocol, radiopharmaceutical dose, and imaging parameters. Summed stress score (SSS), summed stress rest, and summed difference scores (SDS), total perfusion deficit (TPD), severity, and extension of myocardial perfusion defects in three coronary artery territories were analyzed, using quantitative perfusion SPECT software. Results Most variables such as SSS, SDS, TPD, severity, and extension of defects showed a significant difference between the two conditions including beta-blocker consumption and after discontinuing beta-blocker consumption before stress imaging (p < 0.05). Moreover, in patients on treatment with metoprolol, all studied factors including SSS, SDS, TPD, severity, and extension of perfusion defects were significantly reduced when patients consumed beta-blockers before SPECT evaluation (p < 0.05). Conclusion Beta-blocker consumption can lead to a decrease in the severity and extent of myocardial perfusion defects and therefore probably a decrease in the sensitivity of myocardial scans. Discontinuation of beta-blocker prior to the dipyridamole myocardial perfusion scan can improve diagnostic accuracy.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Beta-Blocker Consumption on the Severity and Extension of Perfusion Defects in Dipyridamole Myocardial Perfusion Single-Photon Emission Computed Tomography

Shahlaee,

Falsoleiman,

Daloee

et al. 2024

World J Nucl Med

View full text Add to dashboard Cite

show abstract

“…In previous studies, dipyridamole had been reported to affect circulatory system through its antiplatelet and vasodilator properties 38 . In vitro studies showed the inhibitory effect of dipyridamole on myofibroblast transition and vascular smooth muscle cell proliferation 39,40 . Nonetheless, as these effects has not been demonstrated in vivo.…”

Section: Discussionmentioning

confidence: 99%

Effects of cardiovascular medications on primary patency of hemodialysis arteriovenous fistula

Chang

Chen

Hsieh

et al. 2020

Sci Rep

View full text Add to dashboard Cite

While the patency of vascular access is essential for hemodialysis patients, optimal pharmaceutical treatment to maintain arteriovenous fistula (AVF) patency remains lacking. As cardiovascular diseases are highly prevalent in patients with end-stage renal disease, various cardiovascular medications have also been used to maintain AVF patency. However, previous studies revealed inconsistent therapeutic effects and a comprehensive evaluation of this issue is needed. The present retrospective, longitudinal cohort study included patients receiving successful AVF creation. The evaluated cardiovascular medications included antiplatelet agents, antihypertensive agents, nitrates and nitrites, statins, dipyridamole, and pentoxifylline. The outcome was AVF primary patency. All laboratory data and medication profiles were recorded at baseline and followed at 3-month interval, until the end of the 2-year study period. Cox proportional regression model with time-dependent covariates was used to evaluate the risk for AVF patency loss. A total of 349 patients were included in the present study, in which 57% were men and the mean age was 65 ± 14 years. Among the included patients, 40% used antiplatelet agents, 27% used dipyridamole and 36% used statins at baseline. Of all the evaluated cardiovascular medications, only dipyridamole showed significant association with a higher risk for loss of AVF patency. To evaluate the effect of combination of antiplatelet agents and dipyridamole, the patients were classified into four groups, I: combine use of antiplatelet agents and dipyridamole, II: antiplatelet only, III: dipyridamole only; IV: none of both were used. Of the four groups, group IV

show abstract

The signal pathway for the repressive effect of dipyridamole on myofibroblast transdifferentiation

Cited by 2 publications

References 12 publications

Effect of Beta-Blocker Consumption on the Severity and Extension of Perfusion Defects in Dipyridamole Myocardial Perfusion Single-Photon Emission Computed Tomography

Effect of Beta-Blocker Consumption on the Severity and Extension of Perfusion Defects in Dipyridamole Myocardial Perfusion Single-Photon Emission Computed Tomography

Effects of cardiovascular medications on primary patency of hemodialysis arteriovenous fistula

Contact Info

Product

Resources

About